ERBB2 and breast carcinoma: In 2007, the American Society of Clinical Oncology Committee recommended the following markers in clinical practice in patients with early breast cancer: ER, PgR, HER2, urokinases plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and certain genes detected with multiparameter gene expression assays (Harris et al, 2007).